Promising developments in new gene editing trials continue to drive investor interest in the growing biotech sector. Potential advancements include the…
McAlinden Research PartnersJuly 22, 2021
New developments in advanced methods of CRISPR, particularly in base and prime editing, continue to propel the popularity of the…
McAlinden Research PartnersSeptember 1, 2020
